Giant Cell Lung Carcinoma: A Case Report of a Rare Histology Type of Non-Small Cell Lung Cancer
Downloads
Introduction: Giant cell carcinoma (GCC) of the lung is a subtype of lung cancer, undifferentiated non-small cell carcinoma, in which there are no features of small cell carcinoma, adenocarcinoma, or squamous cell carcinoma. Due to its aggressive clinical manifestations and peculiar pathological features, GCC of the lung is a highly anaplastic variant of bronchogenic carcinoma.
Case: A 45-year-old woman was clinically suspected of having a lung malignancy, and a biopsy of the right lower lobe pleura and parietal pleura was performed. The histopathology showed hypercellular tumor cell clusters, forming a syncytia-like sheet pattern. Tumor cells were pleomorphic and contained many giant cells that confirmed the diagnosis of GCC. The patient was diagnosed with GCC of the lung, stage IVB, Karnofsky scores 50-60% with malignant pleural effusion, peritoneal metastases, bone metastases, and grade 3 malignant ascites with bacterial peritonitis. The patient passed away due to septic shock caused by bacterial peritonitis. GCC of the lung is one of the aggressive types of lung cancer. GCC has an unusual tendency to metastasize to the gastrointestinal tract. In this case, the patient had an enlarged abdomen since it was known that she had a malignancy that had continued to grow. From the ascitic fluid analysis, a carcinoma was found to be seeding.
Conclusion: The prognosis of GCC of the lung is generally poor. Our case was diagnosed with GCC of the lung that had already spread to the bone, peritoneal, and had grade ascites. The patient's survival rate was generally poor, and she passed away due to bacterial peritonitis without having received any therapy for her cancer.
Jones GS, Elimian K, Baldwin DR, et al. A Systematic Review of Survival Following Anti-Cancer Treatment for Small Cell Lung Cancer. Lung Cancer 2020; 141: 44–55. [PubMed]
Chiu Y-W, Kao Y-H, Simoff MJ, et al. Costs of Biopsy and Complications in Patients with Lung Cancer. Clinicoecon Outcomes Res 2021; 13: 191–200. [PubMed]
Chaft JE, Shyr Y, Sepesi B, et al. Preoperative and Postoperative Systemic Therapy for Operable Non–Small-Cell Lung Cancer. J Clin Oncol 2022; 40: 546–555. [PubMed]
Indonesia KKR. Pedoman Nasional Pelayanan Kedokteran Tatalaksana Kanker Paru. Jakarta, 2023.
Suster DI, Mino-Kenudson M. Molecular Pathology of Primary Non-small Cell Lung Cancer. Arch Med Res 2020; 51: 784–798. [PubMed]
Saito T, Tsuta K, Fukumoto KJ, et al. Combined Small Cell Lung Carcinoma and Giant Cell Carcinoma: A Case Report. Surg Case Reports 2017; 3: 52. [PubMed]
Mihajlović J, Diehl LAM, Hochhaus A, et al. Inhibition of Bone Morphogenetic Protein Signaling Reduces Viability, Growth and Migratory Potential of Non-Small Cell Lung Carcinoma Cells. J Cancer Res Clin Oncol 2019; 145: 2675–2687. [PubMed]
Nakayama S, Sasaki M, Morinaga S, et al. Nonsmall Cell Lung Carcinoma with Giant Cell Features Expressing Programmed Death-Ligand 1: A Report of a Patient Successfully Treated with Pembrolizumab. Case Reports in Oncological Medicine 2018; 2018: 5863015. [PubMed]
Ferrer-Inaebnit E, Molina-Romero FX, Pujol-Cano N, et al. Low Digestive Hemorrhage due to Giant-Cell Lung Carcinoma Metastasis. Gastroenterologia y Hepatologia 2021; 44: 223–225. [PubMed]
Al-Zalabani AH. Cancer Incidence Attributable to Tobacco Smoking in GCC Countries in 2018. Tob Induc Dis 2020; 18: 18. [PubMed]
Morimoto T, Yamasaki K, Shingu T, et al. Autopsy Case of a Patient with Rapidly Progressive Combined Small-Cell Lung Carcinoma with Spindle-Shaped Cell Tumor. Thoracic Cancer 2022; 13: 2279–2282. [PubMed]
Nambirajan A, Dutta R, Malik PS, et al. Cytology of SMARCA4-Deficient Thoracic Neoplasms: Comparative Analysis of SMARCA4-Deficient Non-Small Cell Lung Carcinomas and SMARCA4-Deficient Thoracic Sarcomas. Acta Cytol 2021; 65: 67–74. [PubMed]
Lantuejoul S, Fernandez-Cuesta L, Damiola F, et al. New Molecular Classification of Large Cell Neuroendocrine Carcinoma and Small Cell Lung Carcinoma with Potential Therapeutic Impacts. Transl Lung Cancer Res 2020; 9: 2233–2244. [PubMed]
Phaniendra A, Jestadi DB, Periyasamy L. Free Radicals: Properties, Sources, Targets, and Their Implication in Various Diseases. Indian J Clin Biochem 2015; 30: 11–26. [PubMed]
Unsal V, Cicek M, Sabancilar Ä°. Toxicity of Carbon Tetrachloride, Free Radicals and Role of Antioxidants. Rev Environ Health 2021; 36: 279–295. [PubMed]
Pourhassan B, Meysamie A, Alizadeh S, et al. Risk of Obstructive Pulmonary Diseases and Occupational Exposure to Pesticides: A Systematic Review and Meta-Analysis. Public Health 2019; 174: 31–41. [PubMed]
Schueler J, Tschuch C, Klingner K, et al. Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization. Cells; 8. Epub ahead of print July 2019. [PubMed]
De Vita A, Vanni S, Miserocchi G, et al. A Rationale for the Activity of Bone Target Therapy and Tyrosine Kinase Inhibitor Combination in Giant Cell Tumor of Bone and Desmoplastic Fibroma: Translational Evidences. Biomedicines; 10. Epub ahead of print February 2022. [PubMed]
Lázaro S, Pérez-Crespo M, Lorz C, et al. Differential Development of Large-Cell Neuroendocrine or Small-Cell Lung Carcinoma upon Inactivation of 4 Tumor Suppressor Genes. Proc Natl Acad Sci U S A 2019; 116: 22300–22306. [PubMed]
Gonzalez D, Dietz RL, Pantanowitz L. Feasibility of a Deep Learning Algorithm to Distinguish Large Cell Neuroendocrine from Small Cell Lung Carcinoma in Cytology Specimens. Cytopathology 2020; 31: 426–431. [PubMed]
Hong JY, Choi MK, Uhm JE, et al. The Role of Palliative Chemotherapy for Advanced Pulmonary Pleomorphic Carcinoma. Med Oncol 2009; 26: 287–291. [PubMed]
Chang Y-L, Wu C-T, Shih J-Y, et al. EGFR and p53 Status of Pulmonary Pleomorphic Carcinoma: Implications for EGFR Tyrosine Kinase Inhibitors Therapy of an Aggressive Lung Malignancy. Ann Surg Oncol 2011; 18: 2952–2960. [PubMed]
Kim R, Keam B, Hahn S, et al. First-Line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non–Small-Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. Clin Lung Cancer 2019; 20: 331-338.e4. [PubMed]
Copyright (c) 2024 Kadek Sri Adi Putri, Ida Ayu Jasminarti Dwi Kusumawardani, Ni Putu Sriwidyani, Ni Luh Gede Yoni Komalasari
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.